156 related articles for article (PubMed ID: 35114800)
1. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Lu S; Yang ZY; Yan C; Liu WT; Ni ZT; Yao XX; Hua ZC; Feng RH; Zheng YN; Wang ZQ; Sah BK; Chen MM; Zhu ZL; He CY; Li C; Yan M; Zhu ZG
Future Oncol; 2022 Mar; 18(10):1175-1183. PubMed ID: 35114800
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
Koemans WJ; van der Kaaij RT; Boot H; Buffart T; Veenhof AAFA; Hartemink KJ; Grootscholten C; Snaebjornsson P; Retel VP; van Tinteren H; Vanhoutvin S; van der Noort V; Houwink A; Hahn C; Huitema ADR; Lahaye M; Los M; van den Barselaar P; Imhof O; Aalbers A; van Dam GM; van Etten B; Wijnhoven BPL; Luyer MDP; Boerma D; van Sandick JW
BMC Cancer; 2019 May; 19(1):420. PubMed ID: 31060544
[TBL] [Abstract][Full Text] [Related]
5. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: A Meta-Analysis.
Gong Y; Wang P; Zhu Z; Zhang J; Huang J; Wang T; Chen J; Xu H
J Surg Res; 2020 Jan; 245():234-243. PubMed ID: 31421368
[TBL] [Abstract][Full Text] [Related]
7. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
[TBL] [Abstract][Full Text] [Related]
8. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis.
Hao Y; Liu Y; Ishibashi H; Wakama S; Nishino E; Yonemura Y
Eur J Surg Oncol; 2019 Aug; 45(8):1493-1497. PubMed ID: 30948161
[TBL] [Abstract][Full Text] [Related]
9. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study.
Glehen O; Passot G; Villeneuve L; Vaudoyer D; Bin-Dorel S; Boschetti G; Piaton E; Garofalo A
BMC Cancer; 2014 Mar; 14():183. PubMed ID: 24628950
[TBL] [Abstract][Full Text] [Related]
10. INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
Ramos MFKP; Pereira MA; Charruf AZ; Victor CR; Gregorio JVAM; Alban LBV; Moniz CMV; Zilberstein B; Mello ES; Hoff PMG; Ribeiro Junior U; Dias AR
Arq Bras Cir Dig; 2023; 36():e1744. PubMed ID: 37466566
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of paclitaxel combined with S-1 in the prevention and treatment of gastric cancer with peritoneal metastasis].
Zhu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Oct; 18(10):979-82. PubMed ID: 26499139
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.
Yuan H; Lu S; Shi M; Yang Z; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
Future Oncol; 2023 Dec; 19(38):2517-2523. PubMed ID: 37212686
[TBL] [Abstract][Full Text] [Related]
14. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
Tu L; Zhang W; Ni L; Xu Z; Yang K; Gou H; Zhu Q; Liu M; Yang Y; Hu J; Qiu M
Cancer Med; 2023 Feb; 12(4):4161-4169. PubMed ID: 36161282
[TBL] [Abstract][Full Text] [Related]
15. Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer.
Yonemura Y; Ishibashi H; Hirano M; Mizumoto A; Takeshita K; Noguchi K; Takao N; Ichinose M; Liu Y; Li Y
Ann Surg Oncol; 2017 Feb; 24(2):478-485. PubMed ID: 27506661
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma.
Badgwell B; Blum M; Das P; Estrella J; Wang X; Ho L; Fournier K; Royal R; Mansfield P; Ajani J
Ann Surg Oncol; 2017 Oct; 24(11):3338-3344. PubMed ID: 28799004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
